With the introduction of the UPC and shifting dynamics in global patent enforcement, life science companies face renewed questions about when to settle, when to litigate, and how to choose the right forum. This candid, cross-sector panel of in-house counsel and litigators will explore how dispute resolution strategy is evolving across the industry.
• Discover how in-house teams weigh the risks and rewards of litigation versus settlement in a post-UPC world.
• Determine whether certain sectors - such as biotech, generics, or medtech - are more inclined to settle and why.
• Discuss practical insights on how to structure licensing negotiations or parallel proceedings to support favourable outcomes.
Speaker(s):
Shohta Ueno
Assistant General Counsel - Dispute Resolution
Regeneron
Session Type:
Panel